A digital therapeutic that helps people with alcohol-related liver disease reduce consumption and maintain abstinence, with breath-based monitoring and behavioural support.
Continued alcohol use is the single largest determinant of prognosis in ARLD, with a high mortality rate within three years. Yet effective, scalable support to sustain behaviour change has been missing.
AlcoChange is software as a medical device that addresses this directly, intended to reduce alcohol use and maintain abstinence in people with established alcohol-related liver disease.
Configured on the CyberLiver platform, AlcoChange pairs a connected breathalyser with a behavioural programme. Its AlcoX engine models increased drinking, relapse and disengagement risk across alcohol-related pathways.
Talk to us about deploying AlcoChange in your service or research programme.
Get in touch